Ana Ruiz-Garcia

List of Publications by Year
in descending order

50 papers	2,054 citations	331670 21 h-index	233421 45 g-index
52 all docs	52 docs citations	52 times ranked	2882 citing authors

#	Article	IF	Citations
1	Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies. Journal of Clinical Pharmacology, 2021, 61, 349-359.	2.0	2
2	Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clinical and Translational Science, 2021, 14, 184-193.	3.1	3
3	Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome. Clinical and Translational Science, 2021, 14, 2171-2183.	3.1	4
4	Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors. Journal of Clinical Pharmacology, 2020, 60, 605-616.	2.0	13
5	An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure. Cancer Chemotherapy and Pharmacology, 2020, 86, 451-459.	2.3	6
6	Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib. Pharmaceutics, 2020, 12, 330.	4.5	12
7	Pharmacokinetic/Pharmacodynamic Modeling to Support the Reâ€approval of Gemtuzumab Ozogamicin. Clinical Pharmacology and Therapeutics, 2019, 106, 1006-1017.	4.7	23
8	Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 211-222.	1.8	26
9	Abstract 3887: Population pharmacokinetic/pharmacodynamic evaluation of the relationship between glasdegib exposure and safety endpoints in cancer patients. , 2019, , .		1
10	Abstract 3889: Population pharmacokinetic/pharmacodynamic evaluation of the effect of glasdegib exposure on cardiac repolarization (QT interval) in cancer patients. , 2019, , .		1
11	Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anti-Cancer Drugs, 2018, 29, 271-280.	1.4	33
12	Population Pharmacokinetic/Pharmacodynamic Evaluation of the Relationship between Glasdegib Treatment/ Exposure and Overall Survival in AML Patients. Blood, 2018, 132, 1450-1450.	1.4	5
13	Effect of food on the bioavailability of palbociclib. Cancer Chemotherapy and Pharmacology, 2017, 79, 527-533.	2.3	22
14	Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach. Journal of Clinical Pharmacology, 2017, 57, 1159-1173.	2.0	30
15	Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers. Journal of Clinical Pharmacology, 2016, 56, 223-230.	2.0	18
16	Methods and strategies for assessing uncontrolled drugâ€"drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 123-135.	1.8	18
17	Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors. , 2016, , 121-150.		1
18	Effect of axitinib on the QT interval in healthy volunteers. Cancer Chemotherapy and Pharmacology, 2015, 75, 619-628.	2.3	13

#	Article	IF	Citations
19	A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers. Journal of Clinical Pharmacology, 2014, 54, 555-562.	2.0	19
20	A phase 2 trial of dacomitinib (PFâ€00299804), an oral, irreversible panâ€HER (human epidermal growth) Tj ETQq0 0 0 rgBT /Overlock 1 prior chemotherapy and erlotinib. Cancer, 2014, 120, 1145-1154.	4.1	125
21	Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemotherapy and Pharmacology, 2014, 74, 1279-1289.	2.3	12
22	Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract. Xenobiotica, 2013, 43, 745-754.	1.1	5
23	A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers. Cancer Chemotherapy and Pharmacology, 2013, 72, 379-385.	2.3	38
24	Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Cancer Chemotherapy and Pharmacology, 2013, 71, 307-319.	2.3	18
25	Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignanciesâ€"results of a phase I dose-escalation study. Investigational New Drugs, 2013, 31, 1487-1498.	2.6	4
26	Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. British Journal of Cancer, 2013, 108, 1393-1401.	6.4	20
27	Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-8.	2.5	140
28	A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Annals of Oncology, 2012, 23, 119-127.	1.2	23
29	Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Panâ€"Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3337-3344.	1.6	247
30	Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Nonâ€"Small-Cell Lung Cancer: A Lead-In Study. Journal of Thoracic Oncology, 2012, 7, 1406-1416.	1.1	22
31	Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Investigational New Drugs, 2012, 30, 2352-2363.	2.6	62
32	Role of the Equilibrative and Concentrative Nucleoside Transporters in the Intestinal Absorption of the Nucleoside Drug, Ribavirin, in Wild-Type and Ent1(â^'/â^') Mice. Molecular Pharmaceutics, 2012, 9, 2442-2449.	4.6	21
33	A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 709-722.	2.3	12
34	Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Investigational New Drugs, 2011, 29, 1449-1458.	2.6	179
35	Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemotherapy and Pharmacology, 2011, 68, 703-712.	2.3	11
36	Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2011, 29, 5561-5561.	1.6	5

#	Article	IF	Citations
37	A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. British Journal of Cancer, 2010, 103, 993-1000.	6.4	17
38	Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. Lung Cancer, 2010, 70, 180-187.	2.0	41
39	Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncology, The, 2009, 10, 794-800.	10.7	287
40	Pharmacokinetics in Drug Discovery. Journal of Pharmaceutical Sciences, 2008, 97, 654-690.	3.3	116
41	In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation within vitro results. Biopharmaceutics and Drug Disposition, 2007, 28, 229-239.	1.9	29
42	Pharmacokinetics of Murine p75-Fc Fusion Protein and MP6-XT22 Anti-Murine TNF-Î± mAb in Mice. Journal of Investigative Dermatology Symposium Proceedings, 2007, 12, 52-56.	0.8	13
43	Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NONMEM. Xenobiotica, 2005, 35, 1067-1088.	1.1	35
44	Kinetic modelling of the intestinal transport of sarafloxacin. Studiesin situin rat andin vitroin Caco-2 cells. Journal of Drug Targeting, 2005, 13, 199-212.	4.4	23
45	PAMPAâ€"a drug absorption in vitro model. European Journal of Pharmaceutical Sciences, 2004, 21, 429-441.	4.0	187
46	Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 55, 241-246.	4.3	32
47	Kinetic Modeling of Triamterene Intestinal Absorption and its Inhibition by Folic Acid and Methotrexate. Journal of Drug Targeting, 2003, 11, 215-223.	4.4	9
48	Kinetic Characterization of Secretory Transport of a New Ciprofloxacin Derivative (CNV97100) across Caco-2 Cell Monolayers**This work has been submitted for the partial fulfillment of the requirement for a Ph.D. Degree in Pharmaceutics at the University of Valencia, Valencia, Spain. Journal of Pharmaceutical Sciences, 2002, 91, 2511-2519.	3.3	23
49	Intrinsic Absolute Bioavailability Prediction in Rats Based on In Situ Absorption Rate Constants and/or In Vitro Partition Coefficients: 6â€Fluoroquinolones. Journal of Pharmaceutical Sciences, 2000, 89, 1395-1403.	3.3	28
50	Pharmacokinetics, bioavailability and absorption of flumequine in the rat. European Journal of Pharmaceutics and Biopharmaceutics, 1999, 48, 253-258.	4.3	20